Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Binimetinib Plus Hydroxychloroquine in KRAS Mutant Metastatic Pancreatic Cancer

NCT04132505 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04132505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04132505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Binimetinib Plus Hydroxychloroquine in KRAS Mutant Metastatic Pancreatic Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
October 22, 2019
Completion date
March 24, 2026
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma, stage iv pancreatic cancer ajcc v8